SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)
Website: www.sinobiopharm.com
(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT
APPROVAL FOR MARKETING OF BENMELSTOBART INJECTION FOR THE INDICATION OF MAINTENANCE THERAPY AFTER CHEMORADIOTHERAPY FOR NON-SMALL CELL LUNG CANCER

The board of directors (the "**Board**") of Sino Biopharmaceutical Limited (the "**Company**", together with its subsidiaries, the "**Group**") announces that a new indication of benmelstobart (Trade name: Andewei (安得衛®)), a national Category 1 innovative drug independently developed by the Group, has been approved by the National Medical Products Administration (NMPA) of China for marketing. It is indicated for the treatment of patients with unresectable stage III non-small cell lung cancer (NSCLC) who have not progressed after platinum-based concurrent or sequential chemoradiotherapy, and who do not carry known epidermal growth factor receptor (EGFR) sensitizing mutations or anaplastic lymphoma kinase (ALK) rearrangements.

The approval was based on the positive results from the R-ALPS study, which were presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (#LBA8004)[1]. The study enrolled patients with locally advanced/unresectable stage III NSCLC without progression after concurrent/sequential chemoradiotherapy, who then received consolidation therapy with either benmelstobart or placebo until disease progression. The primary endpoint was progression-free survival (PFS) assessed by blinded independent central review (BICR). As shown by the results from the study:

- With a median follow-up of 19.4 months, the median PFS was 9.69 months in the benmelstobart group compared to 4.17 months in the placebo group (HR=0.53，95% CI 0.39-0.72，*p<0.0001*), representing a 47% reduction in the risk of disease progression or death;

- Prespecified subgroup analyses (smoking status, prior treatment as concurrent/sequential) demonstrated consistent benefit trends across all subgroups and the intention-to-treat (ITT) population, indicating the broad applicability of the treatment regimen;

- Overall survival (OS) data were not yet mature, median OS was not reached, with an HR of 0.76 (0.50, 1.14), a promising trend toward OS benefit was observed in the benmelstobart group;

- In terms of safety, the incidence rate of Grade ≥3 treatment-related adverse events (TRAEs) was 29.4% in the benmelstobart group and 19.7% in the placebo group.

Benmelstobart is the third domestic PD-L1 inhibitor approved for consolidation therapy after radical chemoradiotherapy in patients with locally advanced/unresectable NSCLC. Looking forward, the Group will continue to advance innovation in the field of lung cancer, developing a diversified pipeline that covers multiple molecular subtypes and treatment scenarios, with the ultimate goal of improving patient survival outcomes and advancing its mission of science for a healthier world.

Source:

[1] Ming Chen, Yongling Ji, Long Chen, et al. R-ALPS: A randomized, double-blind, placebo-controlled, multicenter phase III clinical trial of TQB2450 with or without anlotinib as maintenance treatment in patients with locally advanced and unresectable (stage III) NSCLC without progression following concurrent or sequential chemoradiotherapy.2025 ASCO (#LBA8004).

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 16 February 2026

As at the date of this announcement, the Board of the Company comprises six executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, and Mr. Tian Zhoushan, and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.